Location:HOME >> Famous Scholars
Directory By Name
 
 
Name: HuangHe
Post Professor
Position: Chancellor,Associate Dean of Zhejiang University School of Medicine
Education Ph.D.
Professional Hematology;Stem Cell and Tissue Engineering
Departments The First Affiliated Hospital
Research Clinical trials and research on hematopoietic stem cell transplantation; Clinical trials and research on hematology; Research on hematological molecular biology; Stem cell research and application
TEL: 0571-88208003
E-mail: hehuangyu@126.com
Personal Home Page:  

Profile

He Huang, M.D., Ph.D., is professor, chancellor and Associate Dean of Zhejiang University School of Medicine, Hangzhou, China. His concurrent appointments include Director of Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, and Vice Director of the Institute of Hematology, Zhejiang University.

Dr. Huang has focused on the clinical practice and research on hematology, and specializes in hematopoietic stem cell transplantation (HSCT). He and his colleagues performed the first unrelated donor BMT in 1998, which was also the first successful unrelated donor BMT for leukemia in China Mainland. Now, the BMT Center has been one of the largest and most successful transplant programs in China. Dr. Huang and his colleagues continue to put great efforts on improving both the effectiveness of HSCT and the long-term quality of life for patients, as well as searching for new transplant strategies. Dr. Huang was awarded the National Prize of Science and Technology for outstanding work on unrelated donor HSCT in China in 2003.

Apart from clinical practice and research on HSCT and its complications, Dr. Huang also devotes himself into basic research, which has three main lines: (1) Pathology of HSCT complications, e.g. genes polymorphism and their role in HSCT outcomes; (2) Stem cell biology and application, including mesenchymal stem cells (MSCs) and introduced pluripotent stem cells (iPS cells). (3) Hematological molecular biology, e.g. network of telomeric binding protein, which is supported by the national basic research program (973 program) in China. Dr. Huang and his group combine important research discoveries with superior clinical techniques to provide the most advanced treatments. During the past years, Dr. Huang published about 170 papers in peer-review journals and awarded 15 national invention patents. With wide national and international collaboration, Dr Huang and his group expect more exciting results in the near future.

Major:
Hematology;Stem Cell and Tissue Engineering

Research Interests:
Clinical trials and research on hematopoietic stem cell transplantation;
Clinical trials and research on hematology;
Research on hematological molecular biology;
Stem cell research and application

Contact Information:
Zhejiang University School of Medicine
No.388 Yuhangtang Road
Hangzhou, Zhejiang, 310058, China.
Tel: +86 571 88208009
Fax: +86 571 88208022
Email: hehuangyu@126.com

Current Position:
Chancellor, Associate Dean of Zhejiang University School of Medicine.
Director of Bone Marrow Transplantation Center, First Affiliated Hospital of Zhejiang University.
Vice Director of Institute of Hematology, Zhejiang University.

Education:
1979 - 1984  Zhejiang University School of Medicine, Bachelor of Medicine.
1987 - 1990  Zhejiang University School of Medicine, Master of Medicine.
1990 - 1993  Zhejiang University School of Medicine, M.D. and Ph.D..

Professional Experience:
1984 - 1987  Resident, Internal Medicine, Jinhua Center Hospital, Zhejiang, China.
1993 - 1997  Physician, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, China.
1997  Advanced Visiting Scholar, Institute of Hematopathology, Kiel University, Germany.
1997 - present  Vice Director, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, China.
1997 - present  Vice Director, Institute of Hematology, Zhejiang University, China.
2000 - present  Professor, Hematology, Zhejiang University School of Medicine, China.
2000 - present  Director, Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, China.
2005 - present  Associate Dean, Zhejiang University School of Medicine, China.
2012 – present  Chancellor, Zhejiang University School of Medicine, China.

Society Membership:
Vice-Director: Hematopoietic Stem Cell Transplantation Committee, Chinese Society of Hematology.
Standing Committee Member: International Scientific Committee, Asian-Pacific Bone Marrow Transplantation Group.
Member: Chinese Society of Hematology.
Standing Committee Member: Society of Hematologic Malignancies, Chinese Anti-Cancer Association.
Chairman: Society of Hematologic Malignancies, Chinese Anti-Cancer Association, Zhejiang Branch, China.
Chairman: Hemato-Immunology Committee, Chinese Society of Immunology, Zhejiang Branch, China.
Chairman (successor): Hematology Committee, Chinese Medical Association, Zhejiang Branch, China
Vice Chairman: Experts Committee, Chinese Marrow Donor Program.
Member of the Council: Chinese Medical Association, Zhejiang Branch, China.
Executive Member of the Council: Society of Immunology, Zhejiang Branch, China.
Member: American Society of Hematology.
Member: European Society of Hematology.
Member: Scientific Advisory Committee, Board of National Representatives International Chronic Myelogenous Leukemia (CML) Foundation
Member: Hemato-Immunology Committee, Chinese Society of Immunology.
Member: Society of Experimental Hematology, Chinese Association of Pathophysiology.
Member: Examining Committee, China Scholarship Council.

Recent Publication(*corresponding author):
1.Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, Yu X,  Cai Z, Lin M, Ye X, Huang H*. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 117: 5257-5260. 2011. (IF: 9.060)
2.Hu Y, Cui Q, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Fu H, Liu L, Fu S, Yu X,  Huang H*. Decitabine facilitates the generation and immunosuppressive function of regulatory gammadeltaT cells derived from human peripheral blood mononuclear cells. Leukemia. 27: 1580-1585. 2013.  (IF: 10.164)
3.Wu K, Wang Y, He Y, Hu Y, Fu H, Sheng L, Wang B, Fu S,  Huang H*. Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment.Leukemia. 28(1):206-210. 2014. (IF: 10.164)
4.He Y, Wu K, Hu Y, Sheng L, Tie R, Wang B, Huang H*. γδ T cell and other immune cells crosstalk in cellular immunity. J Immunol Res. 2014 Mar 6  (Epub ahead of print)
5.Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y, Zheng G, Zhao Y, Ye X, Cai Z, Huang H*. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion. 2013 Dec 23 (Epub ahead of print) (IF: 3.526)
6.Wu K, Zhao Y, He Y, Wang B, Du K, Fu S, Hu K, Zhang L, Liu L, Hu Y, Wang Y,  Huang H*. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.Leuk Lymphoma. 55(3):668-676. 2014. (IF: 2.301)
7.Gu Y, Hu Y, Hu K, Liao W, Zheng F, Yu X, Huang H*. Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells. J Immunol Methods. 402(1-2):82-87. 2014. (IF: 2.225)
8.Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Ye X, Yu X, Cai Z, Lin M, Huang H*. Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplant. 49(2):241-247. 2014. (IF: 3.541)
9.Sun J, Fu S, Zhong W, Huang H*. PML overexpression inhibits proliferation and promotes the osteogenic differentiation of human mesenchymal stem cells. Oncol Rep. 30(6):2785-94. 2013. (IF: 2.297)
10.Jiang Y, Xie W, Hu K, Sun J, Zhu X, Huang H*. An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature. Oncol Lett. 6(4):1120-1122. 2013. (IF: 0.237)
11.Zhu X, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, Lin M, Cai Z, Huang H*.Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation. Leuk Res . 37(9): 1046-51. 2013. (IF: 2.764)
12.Sheng L, Fu S, Hu Y, Fu H, Huang H*. Rapid mobilization of fully functional natural killer cells into blood by AMD3100. Transfusion. 53(9):2108-1010. 2013. (IF: 3.526)
13.Xie W, Zhou D, Hu K, Xiao X, Huang W, He J, Shi J, Luo Y, Zhang J, Lin M, Cai Z, Huang H, Ye X*. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. Exp Ther Med. 6(1):109-114. 2013. (IF: 0.344)
14.Zhao Y, Huang H, Wei G*. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol. 6:40. 2013. (IF: 4.458)
15.Zhang L, Zheng W, Wang Y, Wang Y, Huang H*. Human bone marrow mesenchymal stem cells support the derivation and propagation of human induced pluripotent stem cells in culture. Cell Reprogram. 15(3):216-223. 2013. (IF2.744)
16.Zhou D, Xie W, Hu K, Huang W, Wei G, He J, Shi J, Luo Y, Li L, Zhu J, Zhang J, Lin M, Ye X, Cai Z, Huang H*. Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases. Asian Pac J Cancer Prev. 14(2):929-34. 2013. (IF: 1.271)
17.Du K, Hu Y, Wu K, Huang H*. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transplant. 27(2):E91-E100. 2013. (IF: 1.634)
18.Zheng W, Wang Y, Chang T, Huang H*, Yee JK*. Significant differences in genotoxicity induced by retrovirus integration in human T cells and induced pluripotent stem cells. Gene. 519(1):142-9. 2013. (IF: 2.196)
19.Xie W, Hu K, Xu F, Zhou D, He J, Shi J, Luo Y, Zhu J, Zhang J, Lin M, Ye X, Huang H, Cai Z*. Clinical analysis and prognostic significance of lymphoma-associated hemophagocytosis in peripheral T cell lymphoma. Ann Hematol. 92(4): 481-486. 2013. (IF: 2.866)
20.Shi J, Meng X, Luo Y, Tan Y, Zhu X, Zheng G, He J, Zheng WY Xie W, Li L, Ye X, Zhang J, Cai Z, Lin M, Huang H*.  Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis. Leuk Res . 37(4):372-7.2013. (IF: 2.764)
21.He J, Zhu L, Ye X, Li L, Zhu J, Zhang J, Xie W, Shi J, Zheng W, Wei G, Sun J, CaiZ, Huang H*.  Clinical Characteristics and Prognosis of 23 Patients With
Nonleukemic Myeloid Sarcoma. Am J Med Sci. Aug. 2013.(Epub ahead of print) (IF: 1.334)
22.Wang C, Xiao H, Ma J, Zhu Y, Yu J, Sun L, Sun H, Liu Y, Jin C, Huang H*.  The F-box protein beta-TrCP promotes ubiquitination of TRF1 and regulates the ALT-associated PML bodies formation in U2OS cells. Biochem Biophys Res Commun. 434(4):728-34. 2013. (IF: 2.406)
23.Xie W, Zhao Y, Cao L, Huang W, Wang Y, Huang H*. Cutaneous blastic plasmacytoid dendritic cell neoplasm occurring after spontaneous remission of acute myeloid leukemia: a case report and review of literature.Med Oncol. 29(4):2417-22. 2012. (IF: 2.147)
24.Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica. 97 (12):1804-1812. 2012. (IF:5.935)
25.Hu Y, Gu Y, Cui Q, Fu H, Sheng L, Wu K, Liu L, Fu S, Yu X, Huang H*. Phytohemagglutinin - activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti - CD122 conditioned NOD/SCID mice. Ann Hematol . 91 (11): 1803-1822. 2012. (IF: 2.866)
26.Zhu Y, Wang C, Lan J, Yu J, Jin C. & Huang H*. Phosphorylation of Tara by Plk1 is essential for faithful chromosome segregation in mitosis. Exp Cell Res. 318 (18), 2344-2352. 2012. (IF3.557)
27.Liu L, Hu K, Wang B, Huang H*,Yu Q*. Mobilization of endogenous stem cells: A new strategy for bone healing. Bone. 51 (3): 633-634. 2012. (IF: 3.823)
28.Wu W, Cao L, Li Y, Yu X, Huang H*, He J. Primary splenic diffuse large B-cell lymphoma in a patient with thymus Rosai-Dorfman disease. Am J Med Sci. 344(2):155-9. 2012. (IF: 1.334)
29.Wu K, Luo Y, Liu L, Zhao Y, Hu Y, Tan Y, Lai X , Huang H*. Twin pregnancy and childbirth after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation combined with imatinib mesylate for chronic myeloid leukaemia: case report and literature review. J Int Med Res . 40:2409-15. 2012. (IF 0.958)
30.Wang T, Huang H,CH Tzeng, Wang P, Wu T, Sun J, Tang J, Hu J, Lin S, Kao R*. Impact of donor characteristics and HLA matching on survival of chinese patients with hematologic malignancies undergoing unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant .18:1939-44. 2012. (IF 3.94)
31.Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J*. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 18:1509-16. 2012. (IF 3.94)
32.Xu Y, Liu L, Zhang L, Fu S, Hu Y, Wang Y, Fu H, Wu K, Xiao H, Liu S, Yu X, Zheng W, Feng B, Huang H*. Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells. PLoS One 7(4): e34321. 2012. (IF:3.73)
33.Zhang L, Wang Y, Huang H*. Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clin Transplant. 26 (4): 511-519. 2012. (IF:1.634)
34.Sun J, Wang Z, Luo Y, Tan Y, David S.Allan, Huang H*. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Acta Haematol. 127:143-148. 2012. (IF: 0.894)
35.Xu Y, Liu L, Zhang L, Fu S, Li R, Hu K and Huang H*.Efficient generation of induced pluripotent stem cells from human bone marrow mesenchymal stem cells. Folia Biol (Praha) . 58(6):221-30. 2012. (IF: 1.219)
36.Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Ye X, Yu X, Lin M, Cai Z, Huang H*. Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 18(2): 273-279. 2012. (IF: 3.940)
37.Hu Y, LuoY, Tan Y, Shi J, Sheng L, Fu H, Liu L, Xu Y, Wu K, Xiao H, Zhang L, Yu X, Cai Z, Huang H*. Donor bone marrow-derived stem cells contribute to oral squamous cell carcinoma transformation in a recipient after hematopoietic stem cell transplantation. Stem Cells Dev. 21: 177-180. 2012. (IF: 4.670)
38.Chang T, Zheng W, Tsark W, Bates S, Huang H, Lin R, Yee JK*.  Phenotypic rescue of Induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells. 29: 2090-2093. 2011. (IF 7.701)
39.Wei G, Ni W, Chiao J, Cai Z, Huang H, Liu D*. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol, 4: 46. 2011. (IF: 4.458)
40.Liu L, Wang Y, Wu K, Fu S, Zhang L, Xu Y, Huang H*. The tyrosine kinase inhibitor nilotinib inhibits proliferation and osteoblast differentiation of human mesenchymal stromal cells. Bone. 49(5):1117-1118. 2011. (IF: 3.823)
41.Liu L, Yu Q, Lin J, Lai X, Cao W, Du K, Wang Y, Wu K, Hu Y, Zhang L, Xiao H, Duan Y, Huang H*. Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev. 20(11):1961-71. 2011. (IF: 2.301)
42.Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M, Huang H*. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. Leu Res. 35: 1307-1311. 2011. (IF: 2.764)
43.Zhao Y, Tan Y, Wu G, Liu L, Wang Y, Luo Y, Shi J, Huang H*. Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol. 94: 156-162. 2011. (IF: 1.681)
44.Hu Y, Cui Q, Liang B,Huang H* Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 17(8): 1099-1111. 2011. (IF: 3.94)
45.Tan Y, Fu H, Luo Y, Shi J, Ye X, Zheng Y, Xiao H, Hu Y, Huang H*.Haploidentical Allogeneic Haematopoietic Stem Cell Transplantation as Salvage Therapy for Engraftment Failure after Unrelated and Autologous Stem Cell Transplantation: a Case Report and Review of the Literature. J Int Med Res. 39: 950-959. 2011. (IF: 0.958)
46.Xiao H, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng W, Zheng G, Han X, Jin L, Zhang L, Wang Y, Yu X, Cai Z, Lin M, Ye X, Huang H*. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in Chinese population. Biol Blood Marrow Transplant. 17: 542-549. 2011. (IF: 3.940)
47.Xiao H, Lai X, LuoY, Shi J, Tan Y, He J, Xie W, Li L, Zhu X, Zhu J, Sun J, Wei G,Jin L,Liu L,Wu K,Yu X, Cai Z, Lin M, Ye X, Huang H*. Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in Chinese population. Bone Marrow Transplant. 46: 400-407. 2011. (IF: 3.541)
48.Wang C, Yu J, Yuan K, Lan J, Jin C*, Huang H*.  Plk1-mediated phosphorylation of PinX1 regulates its stability. Eur J Cell Biol. 89(10): 748-756. 2010. (IF: 3.213)
49.Hu Y, Cui Q, Liang B, Huang H*. Donor-derived solid malignancies after hematopoietic stem cell transplantation. Onkologie. 33(4):195-200. 2010. (IF: 1.000)
50.Wu G, Zhao Y, Lai X, Luo Y, Tan Y, Shi J, Li L, Zheng W, Zhang J, Hu X, Jin A, He J, Xie W, Ye X, Cai Z, Lin M, Huang H*. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. Bone Marrow Transplant. 45: 1514-1521. 2010. (IF: 3.541)
51.Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H*, Yen Y. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Res. 30(6): 1921-1930. 2010. (IF: 1.713)
52.Dong-Wook Kim*, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, Huang H, Ian Irving, Saengsuree Jootar, Hyun-Gyung Goh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman, Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, Jianmin Wang, Raymond Wong. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 34(11): 1459-1471. 2010. (IF: 2.764)
53.Yu J, Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C*, Huang H*. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 291(2): 177-186. 2010. (IF: 4.258)
54.Wu G, Zhao Y, Lai X, Yang K, Zhu F, Zhang W, Wang W, Luo Y, Tan Y, Wang Y, Cao W, Huang H*. Distribution of killer-cell immunoglobulin-like receptor genes in Eastern mainland Chinese Han and Taiwanese Han populations. Tissue Antigens. 74(6): 499-507. 2009. (IF: 2.753)
55.Wu Q, Hu H, Lan J, Emenari C, Wang Z, Chang K, Huang H, Yao X*. PML3 Orchestrates the Nuclear Dynamics and Function of TIP60. J Biol Chem. 284(13):8747-8759. 2009. (IF: 4.651)
56.Luo Y, Lai X, Tan Y, Shi J, Zhao Y, Han X, Zheng G, Zhu X, Sun J, Zheng Y, Wu G, He J, Chen S, Jin A, Xie W, Ye X, Cai Z, Lin M, Huang H*. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia. 23(6):1171-1174. 2009. (IF: 10.164)
57.Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z, Lin M, Huang H*. Efficacy and Prognosis of Chronic Myeloid Leukemia Treated With Imatinib Mesylate in a Chinese Population. Int J Hematol. 89(4):445-451. 2009. (IF: 1.681)
58.Zhao Y, Wu G, Wu K, Liu L, Cao W, Yu X, Luo Y, Shi J, Tan Y, Huang H*.  Simultaneous occurrence of variant Philadelphia translocations and ABL mutations in two patients with chronic myeloid leukemia. Leuk Res. 33(7):e85-87. 2009. (IF: 2.764)
59.Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z*. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 33(12):1615-1618. 2009. (IF: 2.764)
60.Qiu L, He J*, Ye X, Xie W, Shi J, Zheng W, Sun J, Zhu X, Cai Z, Huang H, Lin M. Invasive pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases. Int J Hematol. 90(1):108-112. 2009. (IF: 1.681)
61.Shi J, Cai Z*, Huang H, Ye X, He J, Xie W, Zhang J, Zhou X, Luo Y, Lin Y, Li L, Zheng W, Wei G, Lin M. Role of CT-guided percutaneous lung biopsy in diagnosis of pulmonary fungal infection in patients with hematologic diseases. Int J Hematol. 89(5):624-627. 2009. (IF: 1.681)